Furthermore, overexpression of FOXM1 or downregulation of FOXO3 also reduces the sensitivity of EGFR/HER2 overexpressing breast cancer cells to tyrosine-kinase receptor inhibitors, such as gefitinib and lapatinib, while inhibition of FOXM1 or re-expression of FOXO3 restores sensitivity to these inhibitors in resistant breast cancer cells [33], [34]. This evidence concerns the gene EGFR and breast cancer.